Literature DB >> 32889835

Comparison of Radiation Treatment Volumes for Borderline Resectable Pancreatic Cancer in Contemporary Clinical Trials.

Trevor S Bluemel1, Jordan Kharofa.   

Abstract

OBJECTIVES: Optimal radiation target volumes for neoadjuvant therapy in patients with borderline resectable pancreatic cancer (BRPCa) are undefined. Most local recurrences are near the celiac axis and superior mesenteric artery. Methods for generating radiation target volumes include symmetric expansion around the tumor or a customized vascular based approach. We investigated 3 current prospective trials' coverage of vascular regions at increased risk of recurrence by comparing them to 2 reference standards.
MATERIALS AND METHODS: Fourteen computed tomography simulation scans from an institutional prospective trial on BRPCa were used to replicate distinct volumes corresponding to each of 3 contemporary BRPCa trials. Trial volumes were compared with 2 reference volumes (vascular planning target volume and Hopkins planning target volume), which were both based on vascular regions at increased risk of recurrence. Boolean operators and DICE analyses were performed to evaluate trial volume coverage of reference standards.
RESULTS: A total of 42 target volumes and 28 reference volumes were created using the 14-patient data set. DICE coefficients were highly variable ranging from 0.11 to 0.99. Mean % coverage of reference volumes ranged from 5.8% to 98.6%.
CONCLUSIONS: The wide range of DICE coefficients and coverage indicate heterogeneity in high risk vascular target coverage using symmetric Boolean expansions from the primary tumor. This approach may inadequately cover regions at high risk of local recurrence in BRPCa. A customized clinical target volume that specifically includes the superior mesenteric artery and celiac axis will improve coverage to this region and will account for individual and tumor variability.

Entities:  

Mesh:

Year:  2020        PMID: 32889835     DOI: 10.1097/COC.0000000000000726

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution.

Authors:  Toshihiko Masui; Kazuyuki Nagai; Takayuki Anazawa; Asahi Sato; Yuichiro Uchida; Kenzo Nakano; Akitada Yogo; Akihiro Kaneda; Naoto Nakamura; Michio Yoshimura; Takashi Mizowaki; Norimitsu Uza; Akihisa Fukuda; Shigemi Matsumoto; Masashi Kanai; Hiroyoshi Isoda; Masaki Mizumoto; Satoru Seo; Koichiro Hata; Kojiro Taura; Yoshiya Kawaguchi; Kyoichi Takaori; Shinji Uemoto; Etsuro Hatano
Journal:  BMC Cancer       Date:  2022-01-29       Impact factor: 4.430

2.  Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation.

Authors:  Bailey Nelson; Michelle Barrord; Kyle Wang; Nolan A Wages; Mickaela Sudhoff; Jordan Kharofa
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.